Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cogent Biosciences, Inc. (COGT)
USD37.37
-0.09 (-0.23%)
US NASDAQ Healthcare Biotechnology
Address
200 Cambridge Park Drive 2140
Waltham, MA, US
Waltham, MA, US
CEO
Andrew R. Robbins
Website
cogentbio.com
IPO
2018-03-29
CIK 1622229 ISIN US19240Q2012
Description
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD37.37
-0.09 (-0.23%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.35
Float Shares
137.07M
Free Float %
84.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.26% | -1.17% | -5.45% | -5.47% | +2.07% | -2.79% | +591.98% | +190.17% | +334.34% | -22.30% | -22.30% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (12 ratings, all time)
Buy
Price Targets & DCF
Current price
37.37
Low
35.00
-6.4%
Consensus
50.00
+33.8%
Median
52.00
+39.1%
High
60.00
+60.5%
DCF (Unlevered)
0.74
-98.0%
DCF (Levered)
0.87
-97.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
85% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 9 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
55.00
+47.2%
|
| Last Quarter | 3 |
47.33
+26.6%
|
| Last Year | 12 |
42.17
+12.8%
|
| All Time | 20 |
32.30
-13.6%
|
Quality scores
Altman Z-Score
9.61
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-3.7% Q1'26: -15.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +2,068.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-34.9% ★ Q1'26: -40.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.77× Q1'26: -0.58× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 8 EPS Ana. |
Dec 2027 8 Rev. Ana. 7 EPS Ana. |
Dec 2028 8 Rev. Ana. 7 EPS Ana. |
Dec 2029 7 Rev. Ana. 2 EPS Ana. |
Dec 2030 7 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
9.73M
est: 8.52M (+14.2%)
|
22.50M
est: 10.71M (+110.0%)
|
7.87M
est: 7.92M (-0.7%)
|
—
|
—
est: 1.51M (-100.0%)
|
11.23M
5.01M – 25.71M
+641.7% YoY
|
348.34M
110.71M – 748.82M
+3,001.5% YoY
|
768.00M
752.65M – 783.34M
+120.5% YoY
|
1.34B
583.78M – 2.86B
+74.1% YoY
|
1.73B
755.14M – 3.70B
+29.4% YoY
|
| EBITDA |
-34.68M
est: 5.11M (-778.3%)
|
-30.89M
est: 6.43M (-580.5%)
|
-34.57M
est: 4.75M (-827.2%)
|
-271.59M
|
-328.74M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-36.01M
est: 5.11M (-804.2%)
|
-32.18M
est: 6.43M (-600.6%)
|
-35.29M
est: 4.75M (-842.4%)
|
-275.94M
|
-333.36M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-34.53M
est: -612.34M (+94.4%)
|
-30.27M
est: -561.86M (+94.6%)
|
-74.81M
est: -398.98M (+81.3%)
|
-255.86M
est: -250.19M (-2.3%)
|
-328.94M
est: -155.68M (-111.3%)
|
-155.12M
-185.59M – -124.65M
+0.4% YoY
|
-153.58M
-172.60M – 117.58M
+1.0% YoY
|
77.94M
13.65M – 142.23M
+150.7% YoY
|
194.76M
52.14M – 483.12M
+149.9% YoY
|
294.51M
78.85M – 730.58M
+51.2% YoY
|
| SGA |
7.45M
est: 10.59M (-29.6%)
|
10.97M
est: 13.31M (-17.6%)
|
17.42M
est: 9.85M (+77.0%)
|
43.28M
|
63.58M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-5.55
est: -5.90 (+5.9%)
|
-3.97
est: -5.41 (+26.6%)
|
-6.00
est: -3.84 (-56.2%)
|
-2.46
est: -2.42 (-1.7%)
|
-2.55
est: -2.27 (-12.5%)
|
-2.24
-2.75 – -1.84
+1.0% YoY
|
-0.77
-2.55 – 1.74
+65.7% YoY
|
0.87
0.20 – 2.10
+213.6% YoY
|
2.88
0.77 – 7.15
+229.8% YoY
|
4.36
1.17 – 10.81
+51.2% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-06 | HC Wainwright & Co. | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-284.82M
OE per share TTM
-3.50
Owner's Yield
-12.24%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
421.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
44
Total invested
208.13M
Insider transactions (90d)
0
Beneficial owners (>5%)
49
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Fairmount Funds Management LLC | 15.23M | 19.99% | — | 15.23M | — | 15.23M | IA | Delaware | 2022-06-21 | ↗ |
| 2 | Fairmount Healthcare Fund II GP LLC | 14.94M | 19.61% | — | 14.94M | — | 14.94M | OO | Delaware | 2022-06-21 | ↗ |
| 3 | Company, L.P. | 5.88M | 9.64% | — | 5.88M | — | — | PN | Delaware | 2022-06-17 | ↗ |
| 4 | Deerfield Mgmt, L.P. | 5.88M | 9.64% | — | 5.88M | — | — | PN | Delaware | 2022-06-17 | ↗ |
| 5 | Deerfield Partners, L.P. | 5.88M | 9.64% | — | 5.88M | — | — | PN | Delaware | 2022-06-17 | ↗ |
| 6 | James E. Flynn | 5.88M | 9.64% | — | 5.88M | — | — | IN | United States | 2022-06-17 | ↗ |
| 7 | Kynam Capital Management GP, LLC | 5.85M | 6.80% | — | 5.85M | — | — | OO | Delaware | 2024-02-14 | ↗ |
| 8 | Kynam Capital Management, LP | 5.85M | 6.80% | — | 5.85M | — | — | IA | Delaware | 2024-02-14 | ↗ |
| 9 | Yue Tang | 5.85M | 6.80% | — | 5.85M | — | — | IN | U.S. | 2024-02-14 | ↗ |
| 10 | Aaron Cowen | 5.48M | 6.40% | — | 5.48M | — | 5.48M | HC, IN | U.S.A. | 2024-02-05 | ↗ |
| 11 | Suvretta Capital Management, LLC | 5.48M | 6.40% | — | 5.48M | — | 5.48M | IA, OO | U.S.A. | 2024-02-05 | ↗ |
| 12 | Abigail P. Johnson | 5.30M | 6.16% | — | — | 5.30M | — | IN | United States of America | 2024-02-09 | ↗ |
| 13 | FMR LLC | 5.30M | 6.16% | 5.30M | — | 5.30M | — | HC | Delaware | 2024-02-09 | ↗ |
| 14 | (1) BlackRock, Inc. | 4.95M | 7.10% | 4.84M | — | 4.95M | — | HC | Delaware | 2023-02-03 | ↗ |
| 15 | Averill Master Fund, Ltd. | 4.87M | 5.70% | — | 4.87M | — | 4.87M | CO | U.S.A. | 2024-02-05 | ↗ |
| 16 | The Vanguard Group - 23-1945930 | 4.53M | 5.27% | — | 107.1K | 4.37M | 160.4K | IA | Pennsylvania | 2024-02-13 | ↗ |
| 17 | VHCP Co-Investment Holdings II, LLC | 4.30M | 9.99% | — | 4.30M | — | 4.30M | OO | Delaware | 2022-02-14 | ↗ |
| 18 | Venrock Healthcare Capital Partners II, L.P. | 4.30M | 9.99% | — | 4.30M | — | 4.30M | PN | Delaware | 2022-02-14 | ↗ |
| 19 | STATE STREET CORPORATION | 4.26M | 6.10% | — | 4.20M | — | 4.26M | HC | BOSTON, MASSACHUSETTS | 2023-02-03 | ↗ |
| 20 | Peter Kolchinsky | 3.61M | 5.49% | — | 3.61M | — | — | HC, IN | Delaware | 2022-09-06 | ↗ |
| 21 | RA Capital Healthcare Fund, L.P. | 3.61M | 5.49% | — | 3.61M | — | — | PN | Delaware | 2022-09-06 | ↗ |
| 22 | RA Capital Management, L.P. | 3.61M | 5.49% | — | 3.61M | — | — | IA, PN | Delaware | 2022-09-06 | ↗ |
| 23 | Rajeev Shah | 3.61M | 5.49% | — | 3.61M | — | — | HC, IN | Delaware | 2022-09-06 | ↗ |
| 24 | Point72 Asset Management, L.P. | 3.56M | 5.00% | — | 3.56M | — | — | PN | Delaware | 2023-06-01 | ↗ |
| 25 | Point72 Capital Advisors, Inc. | 3.56M | 5.00% | — | 3.56M | — | — | CO | Delaware | 2023-06-01 | ↗ |
| 26 | Steven A. Cohen | 3.56M | 5.00% | — | 3.56M | — | — | IN | Delaware | 2023-06-01 | ↗ |
| 27 | Eventide Asset Management, LLC | 3.51M | 8.80% | 3.51M | — | 3.51M | — | IA | Delaware | 2022-02-14 | ↗ |
| 28 | Robin C. John | 3.51M | 8.80% | — | 3.51M | — | — | HC, IN | United States | 2022-02-14 | ↗ |
| 29 | Fairmount Healthcare Fund GP LLC | 3.27M | 4.90% | — | 3.27M | — | 3.27M | OO | Delaware | 2022-06-21 | ↗ |
| 30 | BVF Partners L.P. | 3.11M | 7.50% | — | — | — | 3.11M | IA, PN | — | 2022-02-14 | ↗ |
| 31 | Commodore Capital LP | 2.28M | 5.70% | — | 2.28M | — | — | IA | Delaware, USA | 2022-02-14 | ↗ |
| 32 | Commodore Capital Master LP | 2.28M | 5.70% | — | 2.28M | — | — | OO | Delaware, USA | 2022-02-14 | ↗ |
| 33 | James Brush | 2.19M | 9.00% | — | 2.19M | — | 2.19M | IN | Delaware | 2022-03-01 | ↗ |
| 34 | Albert Cha | 2.19M | 5.50% | — | 2.19M | — | 2.19M | IN | Delaware | 2022-03-01 | ↗ |
| 35 | FHMLSP, L.L.C | 2.19M | 5.50% | — | 2.19M | — | 2.19M | OO | Delaware | 2022-03-01 | ↗ |
| 36 | FHMLSP, L.P. | 2.19M | 5.50% | — | 2.19M | — | 2.19M | PN | Delaware | 2022-03-01 | ↗ |
| 37 | Frazier Life Sciences Public Fund L.P. | 2.19M | 5.50% | — | 2.19M | — | 2.19M | PN | Delaware | 2022-03-01 | ↗ |
| 38 | James N. Topper | 2.19M | 5.50% | — | 2.19M | — | 2.19M | IN | Delaware | 2022-03-01 | ↗ |
| 39 | Patrick J. Heron | 2.19M | 5.50% | — | 2.19M | — | 2.19M | IN | Delaware | 2022-03-01 | ↗ |
| 40 | BVF I GP LLC | 1.70M | 4.20% | — | — | — | 1.70M | OO | — | 2022-02-14 | ↗ |
| 41 | Biotechnology Value Fund, L.P. | 1.70M | 4.20% | — | — | — | 1.70M | PN | — | 2022-02-14 | ↗ |
| 42 | Arsani William | 150.0K | 11.00% | — | 150.0K | — | 150.0K | HC, IN | United States | 2022-02-14 | ↗ |
| 43 | Graham Walmsley | 150.0K | 11.00% | — | 150.0K | — | 150.0K | HC, IN | United States | 2022-02-14 | ↗ |
| 44 | Logos Global Management GP LLC | 150.0K | 11.00% | — | 150.0K | — | 150.0K | HC, OO | Delaware | 2022-02-14 | ↗ |
| 45 | Logos Global Management LP | 150.0K | 11.00% | — | 150.0K | — | 150.0K | IA, PN | Delaware | 2022-02-14 | ↗ |
| 46 | Logos Global Opportunities Fund II LP | 150.0K | 11.00% | — | 150.0K | — | 150.0K | PN | Delaware | 2022-02-14 | ↗ |
| 47 | Logos Opportunities GP LLC | 150.0K | 11.00% | — | 150.0K | — | 150.0K | OO | Delaware | 2022-02-14 | ↗ |
| 48 | Ridgeback Capital Investments LLC 72-1614961 | — | 0.00% | — | — | — | — | OO | Delaware | 2022-02-14 | ↗ |
| 49 | Ridgeback Capital Management LLC 42-1684320 | — | 0.00% | — | — | — | — | OO | Delaware | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
44
-230 vs prev Q
New positions
14
Closed positions
238
Increased
29
Reduced
11
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 1.17M +1.2M (+100.0%) | 41.58B +41.6B (+100.0%) | 1.73% +1.732 pp | 12.27% +12.272 pp | USD35.52 +0.0% | 1 qtrs NEW |
| 2 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 305.9K +305.9K (+100.0%) | 10.87B +10.9B (+100.0%) | 0.45% +0.453 pp | 0.02% +0.016 pp | USD35.52 +0.0% | 1 qtrs NEW |
| 3 | FMR LLC | 23.09M +678.7K (+3.0%) | 820.05M +498.3M (+154.8%) | 20.17% +0.593 pp | 0.04% +0.025 pp | USD10.49 +238.6% | 18 qtrs — |
| 4 | BLACKROCK, INC. | 12.97M +2.6M (+25.1%) | 460.86M +312.0M (+209.5%) | 19.19% +10.134 pp | 0.01% +0.005 pp | USD16.04 +121.4% | 6 qtrs — |
| 5 | VANGUARD GROUP INC | 11.51M +3.8M (+48.4%) | 408.99M +297.6M (+267.1%) | 17.03% +10.256 pp | 0.01% +0.004 pp | USD18.57 +91.3% | 21 qtrs — |
| 6 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 9.04M -9.2K (-0.1%) | 321.24M +191.2M (+147.1%) | 13.38% +5.470 pp | 4.10% +2.118 pp | USD12.76 +178.4% | 21 qtrs — |
| 7 | FAIRMOUNT FUNDS MANAGEMENT LLC | 9.00M +— (+0.0%) | 319.80M +190.5M (+147.4%) | 7.87% +0.000 pp | 24.34% +12.709 pp | USD11.01 +222.6% | 21 qtrs — |
| 8 | RTW INVESTMENTS, LP | 7.59M +4.1M (+119.0%) | 269.68M +219.9M (+441.6%) | 11.23% +8.202 pp | 2.70% +2.088 pp | USD25.86 +37.4% | 2 qtrs — |
| 9 | KYNAM CAPITAL MANAGEMENT, LP | 6.17M -1.7M (-21.8%) | 218.99M +105.7M (+93.4%) | 5.39% -1.504 pp | 13.99% +5.557 pp | USD7.59 +368.0% | 17 qtrs — |
| 10 | TCG CROSSOVER MANAGEMENT, LLC | 5.87M -930.0K (-13.7%) | 208.44M +110.8M (+113.5%) | 5.13% -0.813 pp | 6.90% +2.096 pp | USD9.47 +275.1% | 17 qtrs — |
| 11 | STATE STREET CORP | 4.94M +164.9K (+3.5%) | 175.48M +106.9M (+155.9%) | 7.31% +3.136 pp | 0.01% +0.004 pp | USD11.27 +215.2% | 21 qtrs — |
| 12 | JANUS HENDERSON GROUP PLC | 4.54M +1.4M (+42.8%) | 161.11M +115.5M (+253.3%) | 3.96% +1.188 pp | 0.07% +0.051 pp | USD16.15 +119.9% | 21 qtrs — |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 3.51M +240.4K (+7.3%) | 124.86M +77.8M (+165.5%) | 5.20% +2.339 pp | 0.01% +0.005 pp | USD12.59 +182.1% | 21 qtrs — |
| 14 | WELLINGTON MANAGEMENT GROUP LLP | 2.71M +2.3M (+566.6%) | 96.34M +90.5M (+1,548.8%) | 2.37% +2.014 pp | 0.02% +0.016 pp | USD31.53 +12.7% | 9 qtrs — |
| 15 | PRICE T ROWE ASSOCIATES INC /MD/ | 2.56M +2.5M (+2,758.0%) | 91.08M +89.8M (+6,965.6%) | 3.79% +3.715 pp | 0.01% +0.010 pp | USD34.64 +2.5% | 14 qtrs — |
| 16 | VIVO CAPITAL, LLC | 2.40M -390.1K (-14.0%) | 85.21M +45.2M (+112.8%) | 3.55% +1.112 pp | 5.51% +2.285 pp | USD12.20 +191.1% | 18 qtrs — |
| 17 | OCTAGON CAPITAL ADVISORS LP | 2.35M -524.1K (-18.2%) | 83.47M +42.2M (+102.2%) | 3.48% +0.965 pp | 10.13% +3.878 pp | USD9.42 +277.1% | 6 qtrs — |
| 18 | D. E. SHAW & CO., INC. | 2.25M +716.9K (+46.8%) | 79.84M +57.9M (+263.2%) | 1.96% +0.626 pp | 0.04% +0.031 pp | USD20.39 +74.2% | 17 qtrs — |
| 19 | DUQUESNE FAMILY OFFICE LLC | 2.21M +1.2M (+109.0%) | 78.66M +63.4M (+416.9%) | 3.28% +2.350 pp | 1.75% +1.376 pp | USD25.40 +39.8% | 2 qtrs — |
| 20 | COMMODORE CAPITAL LP | 2.20M -5.1M (-69.7%) | 78.03M -26.1M (-25.0%) | 3.25% -3.084 pp | 5.19% +0.112 pp | USD12.44 +185.5% | 21 qtrs — |
| 21 | VR ADVISER, LLC | 2.00M -2.0M (-50.0%) | 71.04M +13.6M (+23.7%) | 1.75% -1.747 pp | 3.51% +0.276 pp | USD9.50 +273.9% | 21 qtrs — |
| 22 | SOFINNOVA INVESTMENTS, INC. | 1.97M -154.3K (-7.3%) | 70.10M +39.5M (+129.4%) | 1.72% -0.135 pp | 3.02% +1.352 pp | USD6.49 +447.3% | 8 qtrs — |
| 23 | LORD, ABBETT & CO. LLC | 1.87M +1.9M (+100.0%) | 66.44M +66.4M (+100.0%) | 1.63% +1.634 pp | 0.20% +0.204 pp | USD35.52 +0.0% | 1 qtrs NEW |
| 24 | GOLDMAN SACHS GROUP INC | 1.71M +45.5K (+2.7%) | 60.57M +36.7M (+154.1%) | 2.52% +1.073 pp | 0.01% +0.005 pp | USD11.08 +220.6% | 21 qtrs — |
| 25 | MARSHALL WACE, LLP | 1.66M +1.0M (+158.5%) | 58.99M +49.8M (+539.4%) | 2.46% +1.895 pp | 0.05% +0.044 pp | USD27.33 +30.0% | 2 qtrs — |
| 26 | SIREN, L.L.C. | 1.63M -95.0K (-5.5%) | 57.87M +33.1M (+133.7%) | 1.42% -0.083 pp | 1.73% +0.758 pp | USD10.80 +228.9% | 3 qtrs — |
| 27 | EMERALD ADVISERS, LLC | 1.58M +3.9K (+0.2%) | 56.24M +33.6M (+148.0%) | 1.38% +0.003 pp | 1.73% +1.006 pp | USD7.86 +351.9% | 3 qtrs — |
| 28 | BALYASNY ASSET MANAGEMENT L.P. | 1.44M -1.2M (-46.1%) | 51.16M +12.8M (+33.4%) | 1.26% -1.075 pp | 0.06% +0.016 pp | USD14.36 +147.4% | 7 qtrs — |
| 29 | CITADEL ADVISORS LLC | 1.44M -228.8K (-13.7%) | 51.11M +27.2M (+113.4%) | 2.13% +0.672 pp | 0.01% +0.004 pp | USD11.44 +210.5% | 21 qtrs — |
| 30 | REDMILE GROUP, LLC | 1.44M -771.2K (-34.9%) | 51.07M +19.4M (+61.0%) | 1.26% -0.674 pp | 3.76% +0.675 pp | USD10.97 +223.8% | 11 qtrs — |
| 31 | CANDRIAM S.C.A. | 1.30M +342.3K (+35.9%) | 46.05M +32.4M (+236.1%) | 1.92% +1.084 pp | 0.23% +0.158 pp | USD17.58 +102.0% | 3 qtrs — |
| 32 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.28M +90.1K (+7.6%) | 45.49M +28.4M (+166.1%) | 1.12% +0.079 pp | 0.01% +0.004 pp | USD12.65 +180.8% | 19 qtrs — |
| 33 | SILVERARC CAPITAL MANAGEMENT, LLC | 1.25M +430.2K (+52.8%) | 44.23M +32.5M (+277.9%) | 1.09% +0.376 pp | 6.14% +4.565 pp | USD21.67 +63.9% | 2 qtrs — |
| 34 | SATURN V CAPITAL MANAGEMENT LLC | 1.22M -808.0K (-39.9%) | 43.23M +14.2M (+48.7%) | 1.06% -0.706 pp | 7.93% +1.556 pp | USD8.31 +327.4% | 11 qtrs — |
| 35 | MILLENNIUM MANAGEMENT LLC | 1.21M +793.3K (+191.2%) | 42.92M +37.0M (+620.2%) | 1.79% +1.425 pp | 0.02% +0.016 pp | USD25.59 +38.8% | 17 qtrs — |
| 36 | NORTHERN TRUST CORP | 1.20M +17.6K (+1.5%) | 42.60M +25.6M (+151.0%) | 1.05% +0.015 pp | 0.01% +0.003 pp | USD11.52 +208.3% | 21 qtrs — |
| 37 | BANK OF AMERICA CORP /DE/ | 1.19M -1.0M (-46.8%) | 42.34M +10.2M (+31.7%) | 1.76% -0.193 pp | 0.00% +0.001 pp | USD9.34 +280.3% | 21 qtrs — |
| 38 | HOLOCENE ADVISORS, LP | 1.18M +1.1M (+899.2%) | 41.85M +40.2M (+2,371.5%) | 1.74% +1.640 pp | 0.09% +0.084 pp | USD33.40 +6.3% | 2 qtrs — |
| 39 | FRED ALGER MANAGEMENT, LLC | 1.10M +1.1M (+100.0%) | 39.15M +39.1M (+100.0%) | 1.63% +1.630 pp | 0.15% +0.154 pp | USD35.52 +0.0% | 1 qtrs NEW |
| 40 | EMERALD MUTUAL FUND ADVISERS TRUST | 1.04M +15.6K (+1.5%) | 36.89M +22.2M (+151.1%) | 0.91% +0.014 pp | 1.80% +1.039 pp | USD8.49 +318.4% | 3 qtrs — |
| 41 | NUVEEN, LLC | 932.6K -7.0K (-0.7%) | 33.13M +19.6M (+145.5%) | 1.38% +0.559 pp | 0.01% +0.005 pp | USD12.31 +188.5% | 4 qtrs — |
| 42 | AMERICAN CENTURY COMPANIES INC | 892.9K +892.9K (+100.0%) | 31.72M +31.7M (+100.0%) | 1.32% +1.321 pp | 0.02% +0.016 pp | USD35.52 +0.0% | 1 qtrs NEW |
| 43 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 849.0K -159.3K (-15.8%) | 30.16M +15.7M (+108.3%) | 0.74% -0.139 pp | 1.55% +0.700 pp | USD8.66 +310.2% | 3 qtrs — |
| 44 | POINT72 ASSET MANAGEMENT, L.P. | 827.5K -410.3K (-33.1%) | 29.39M +11.6M (+65.4%) | 0.72% -0.359 pp | 0.03% +0.003 pp | USD9.10 +290.3% | 21 qtrs — |
| 45 | FIRST TURN MANAGEMENT, LLC | 824.3K +824.3K (+100.0%) | 29.28M +29.3M (+100.0%) | 0.72% +0.720 pp | 3.35% +3.345 pp | USD35.52 +0.0% | 1 qtrs NEW |
| 46 | WOODLINE PARTNERS LP | 818.8K +305.4K (+59.5%) | 29.08M +21.7M (+294.5%) | 1.21% +0.763 pp | 0.11% +0.078 pp | USD17.12 +107.5% | 10 qtrs — |
| 47 | MORGAN STANLEY | 726.8K -561.4K (-43.6%) | 25.82M +7.3M (+39.6%) | 1.08% -0.050 pp | 0.00% +0.000 pp | USD6.86 +417.8% | 21 qtrs — |
| 48 | RENAISSANCE TECHNOLOGIES LLC | 689.1K +456.1K (+195.8%) | 24.48M +21.1M (+631.6%) | 1.02% +0.816 pp | 0.04% +0.034 pp | USD28.37 +25.2% | 5 qtrs — |
| 49 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 669.0K +669.0K (+100.0%) | 23.76M +23.8M (+100.0%) | 0.99% +0.990 pp | 0.08% +0.084 pp | USD35.52 +0.0% | 1 qtrs NEW |
| 50 | INVESCO LTD. | 585.8K +213.5K (+57.3%) | 20.81M +15.5M (+289.2%) | 0.87% +0.541 pp | 0.00% +0.002 pp | USD20.83 +70.5% | 21 qtrs — |
| 51 | ATIKA CAPITAL MANAGEMENT LLC | 506.0K +506.0K (+100.0%) | 17.97M +18.0M (+100.0%) | 0.75% +0.749 pp | 1.89% +1.892 pp | USD35.52 +0.0% | 1 qtrs NEW |
| 52 | ALYESKA INVESTMENT GROUP, L.P. | 493.9K +393.9K (+393.9%) | 17.54M +16.1M (+1,121.8%) | 0.73% +0.643 pp | 0.05% +0.045 pp | USD31.24 +13.7% | 2 qtrs — |
| 53 | DEEP TRACK CAPITAL, LP | 453.1K +453.1K (+100.0%) | 16.09M +16.1M (+100.0%) | 0.40% +0.396 pp | 0.29% +0.287 pp | USD35.52 +0.0% | 1 qtrs NEW |
| 54 | J. GOLDMAN & CO LP | 439.3K +439.3K (+100.0%) | 15.60M +15.6M (+100.0%) | 0.65% +0.650 pp | 0.41% +0.411 pp | USD35.52 +0.0% | 1 qtrs NEW |
| 55 | FEDERATED HERMES, INC. | 426.8K +333.6K (+357.8%) | 15.16M +13.8M (+1,032.4%) | 0.37% +0.291 pp | 0.03% +0.023 pp | USD30.90 +15.0% | 7 qtrs — |
| 56 | ENSIGN PEAK ADVISORS, INC | 421.5K +395.9K (+1,545.0%) | 14.97M +14.6M (+3,969.1%) | 0.37% +0.346 pp | 0.03% +0.026 pp | USD33.77 +5.2% | 4 qtrs — |
| 57 | JPMORGAN CHASE & CO | 400.9K +326.1K (+435.9%) | 14.24M +13.2M (+1,225.6%) | 0.35% +0.285 pp | 0.00% +0.001 pp | USD30.63 +16.0% | 21 qtrs — |
| 58 | RUSSELL INVESTMENTS GROUP, LTD. | 385.5K +264.5K (+218.7%) | 13.69M +12.0M (+688.3%) | 0.34% +0.231 pp | 0.01% +0.013 pp | USD27.05 +31.3% | 12 qtrs — |
| 59 | SPHERA FUNDS MANAGEMENT LTD. | 378.5K +280.0K (+284.2%) | 13.44M +12.0M (+850.2%) | 0.56% +0.474 pp | 2.60% +2.301 pp | USD27.83 +27.6% | 4 qtrs — |
| 60 | BANK OF NEW YORK MELLON CORP | 376.3K +13.3K (+3.7%) | 13.37M +8.2M (+156.4%) | 0.33% +0.012 pp | 0.00% +0.001 pp | USD13.42 +164.7% | 14 qtrs — |
| 61 | RAYMOND JAMES FINANCIAL INC | 375.9K +86.5K (+29.9%) | 13.35M +9.2M (+221.3%) | 0.33% +0.076 pp | 0.00% +0.003 pp | USD19.23 +84.7% | 3 qtrs — |
| 62 | ASSENAGON ASSET MANAGEMENT S.A. | 375.6K -201.4K (-34.9%) | 13.34M +5.1M (+61.0%) | 0.33% -0.176 pp | 0.02% +0.007 pp | USD12.55 +183.0% | 15 qtrs — |
| 63 | ORBIMED ADVISORS LLC | 371.0K +371.0K (+100.0%) | 13.18M +13.2M (+100.0%) | 0.55% +0.549 pp | 0.27% +0.270 pp | USD35.52 +0.0% | 1 qtrs NEW |
| 64 | SUPERSTRING CAPITAL MANAGEMENT LP | 366.2K +4.8K (+1.3%) | 13.01M +7.8M (+150.7%) | 0.54% +0.226 pp | 6.96% +1.852 pp | USD8.05 +341.2% | 5 qtrs — |
| 65 | KENNEDY CAPITAL MANAGEMENT LLC | 352.4K -231.5K (-39.6%) | 12.52M +4.1M (+49.3%) | 0.52% +0.011 pp | 0.27% +0.080 pp | USD9.43 +276.7% | 14 qtrs — |
| 66 | AFFINITY ASSET ADVISORS, LLC | 350.0K +350.0K (+100.0%) | 12.43M +12.4M (+100.0%) | 0.31% +0.306 pp | 0.71% +0.708 pp | USD35.52 +0.0% | 1 qtrs NEW |
| 67 | HENNION & WALSH ASSET MANAGEMENT, INC. | 338.1K +37.9K (+12.6%) | 12.01M +7.7M (+178.6%) | 0.30% +0.033 pp | 0.41% +0.258 pp | USD11.57 +207.0% | 7 qtrs — |
| 68 | HIGHVISTA STRATEGIES LLC | 336.7K -125.7K (-27.2%) | 11.96M +5.3M (+80.1%) | 0.50% +0.094 pp | 3.08% +1.452 pp | USD12.01 +195.8% | 14 qtrs — |
| 69 | BURKEHILL GLOBAL MANAGEMENT, LP | 325.0K +125.0K (+62.5%) | 11.54M +8.7M (+301.9%) | 0.48% +0.306 pp | 0.76% +0.597 pp | USD22.50 +57.9% | 2 qtrs — |
| 70 | BARCLAYS PLC | 321.6K +145.9K (+83.1%) | 11.42M +9.5M (+502.1%) | 0.48% +0.322 pp | 0.00% +0.002 pp | USD20.92 +69.8% | 16 qtrs — |
| 71 | PATIENT SQUARE CAPITAL LP | 317.4K +317.4K (+100.0%) | 11.27M +11.3M (+100.0%) | 0.28% +0.277 pp | 2.41% +2.413 pp | USD35.52 +0.0% | 1 qtrs NEW |
| 72 | EXOME ASSET MANAGEMENT LLC | 305.6K -138.0K (-31.1%) | 10.85M +4.5M (+70.4%) | 0.45% +0.065 pp | 5.19% +1.333 pp | USD5.99 +493.0% | 4 qtrs — |
| 73 | MAN GROUP PLC | 292.1K +292.1K (+100.0%) | 10.37M +10.4M (+100.0%) | 0.26% +0.255 pp | 0.02% +0.018 pp | USD35.52 +0.0% | 1 qtrs NEW |
| 74 | QUBE RESEARCH & TECHNOLOGIES LTD | 276.7K +163.1K (+143.5%) | 9.83M +8.2M (+502.2%) | 0.24% +0.143 pp | 0.01% +0.008 pp | USD26.34 +34.9% | 3 qtrs — |
| 75 | UBS GROUP AG | 264.0K -1.6M (-85.8%) | 9.38M -17.2M (-64.8%) | 0.39% -1.229 pp | 0.00% -0.003 pp | USD6.23 +470.1% | 18 qtrs — |
| 76 | SUMMITTX CAPITAL, L.P. | 257.2K -38.6K (-13.1%) | 9.13M +4.9M (+115.0%) | 0.38% +0.122 pp | 0.28% +0.100 pp | USD6.00 +492.0% | 4 qtrs — |
| 77 | EVERGREEN QUALITY FUND GP, LTD. | 250.0K +250.0K (+100.0%) | 8.88M +8.9M (+100.0%) | 0.22% +0.218 pp | 0.18% +0.175 pp | USD35.52 +0.0% | 1 qtrs NEW |
| 78 | NANTAHALA CAPITAL MANAGEMENT, LLC | 250.0K -1.3M (-83.4%) | 8.88M -12.8M (-59.0%) | 0.22% -1.098 pp | 0.29% -0.458 pp | USD8.09 +339.1% | 11 qtrs — |
| 79 | NWI MANAGEMENT LP | 241.7K +241.7K (+100.0%) | 8.58M +8.6M (+100.0%) | 0.36% +0.358 pp | 0.40% +0.395 pp | USD35.52 +0.0% | 1 qtrs NEW |
| 80 | F/M INVESTMENTS LLC | 235.8K +15.6K (+7.1%) | 8.38M +5.2M (+164.9%) | 0.21% +0.014 pp | 0.32% +0.196 pp | USD12.11 +193.3% | 3 qtrs — |
| 81 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 229.8K +— (+0.0%) | 8.16M +4.9M (+147.4%) | 0.34% +0.139 pp | 0.13% +0.074 pp | USD11.37 +212.4% | 3 qtrs — |
| 82 | ALGERT GLOBAL LLC | 227.9K -39.3K (-14.7%) | 8.09M +4.3M (+111.0%) | 0.34% +0.104 pp | 0.13% +0.062 pp | USD7.29 +387.2% | 14 qtrs — |
| 83 | BOXER CAPITAL MANAGEMENT, LLC | 225.0K +225.0K (+100.0%) | 7.99M +8.0M (+100.0%) | 0.20% +0.197 pp | 1.75% +1.749 pp | USD35.52 +0.0% | 1 qtrs NEW |
| 84 | CORMORANT ASSET MANAGEMENT, LP | 225.0K +225.0K (+100.0%) | 7.99M +8.0M (+100.0%) | 0.20% +0.197 pp | 0.37% +0.370 pp | USD35.52 +0.0% | 1 qtrs NEW |
| 85 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 211.6K +12.5K (+6.3%) | 7.52M +4.7M (+162.9%) | 0.31% +0.139 pp | 0.00% +0.001 pp | USD12.30 +188.8% | 10 qtrs — |
| 86 | BNP PARIBAS ARBITRAGE, SNC | 199.0K -499.0K (-71.5%) | 7.07M -3.0M (-29.5%) | 0.29% -0.315 pp | 0.00% -0.002 pp | USD12.15 +192.3% | 5 qtrs — |
| 87 | AMERIPRISE FINANCIAL INC | 188.3K +188.3K (+100.0%) | 6.69M +6.7M (+100.0%) | 0.16% +0.165 pp | 0.00% +0.002 pp | USD35.52 +0.0% | 1 qtrs NEW |
| 88 | RHUMBLINE ADVISERS | 180.2K +3.5K (+2.0%) | 6.40M +3.9M (+152.2%) | 0.27% +0.112 pp | 0.01% +0.003 pp | USD10.50 +238.3% | 19 qtrs — |
| 89 | ALLIANCEBERNSTEIN L.P. | 155.5K +30.9K (+24.8%) | 5.52M +3.7M (+208.7%) | 0.23% +0.121 pp | 0.00% +0.001 pp | USD15.39 +130.8% | 15 qtrs — |
| 90 | WELLS FARGO & COMPANY/MN | 153.6K +72.6K (+89.7%) | 5.46M +4.3M (+369.1%) | 0.23% +0.157 pp | 0.00% +0.001 pp | USD22.40 +58.6% | 21 qtrs — |
| 91 | JANE STREET GROUP, LLC | 135.3K +121.6K (+887.6%) | 4.81M +4.6M (+2,342.8%) | 0.20% +0.188 pp | 0.00% +0.001 pp | USD33.38 +6.4% | 2 qtrs — |
| 92 | DIADEMA PARTNERS LP | 131.9K +34.0K (+34.8%) | 4.68M +3.3M (+233.4%) | 0.20% +0.110 pp | 0.81% +0.448 pp | USD13.92 +155.2% | 5 qtrs — |
| 93 | PERCEPTIVE ADVISORS LLC | 121.1K +121.1K (+100.0%) | 4.30M +4.3M (+100.0%) | 0.18% +0.179 pp | 0.08% +0.077 pp | USD35.52 +0.0% | 1 qtrs NEW |
| 94 | PRUDENTIAL FINANCIAL INC | 120.2K +104.8K (+680.6%) | 4.27M +4.0M (+1,830.9%) | 0.18% +0.164 pp | 0.01% +0.005 pp | USD32.04 +10.9% | 3 qtrs — |
| 95 | RAFFERTY ASSET MANAGEMENT, LLC | 111.1K -37.7K (-25.3%) | 3.95M +1.8M (+84.7%) | 0.16% +0.034 pp | 0.01% +0.007 pp | USD10.62 +234.5% | 14 qtrs — |
| 96 | NEOS INVESTMENT MANAGEMENT LLC | 107.9K +18.0K (+20.0%) | 3.83M +2.5M (+196.9%) | 0.16% +0.081 pp | 0.02% +0.013 pp | USD12.03 +195.3% | 9 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
686.00
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+686
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 686 | 35.24 | 24.2K | 686 | D | ↗ |
| 2026-03-31 | Fairmount Funds Management LLC | Director | C-Conversion | A | Common Stock | 7,000,000 | 0.00 | — | 12,503,418 | I | ↗ |
| 2026-01-22 | Fairmount Funds Management LLC | Director | S-Sale | D | Common Stock | 3,500,000 | 36.40 | 127.40M | 5,503,418 | I | ↗ |
| 2026-01-01 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 643 | 34.74 | 22.3K | 643 | D | ↗ |
| 2025-12-26 | Sachs Jessica | Officer | S-Sale | D | Common Stock | 82,642 | 38.70 | 3.20M | 133,938 | D | ↗ |
| 2025-12-26 | Robinson John Edward | Officer | S-Sale | D | Common Stock | 90,000 | 38.74 | 3.49M | 140,002 | D | ↗ |
| 2025-12-26 | Kearns Evan | Officer | S-Sale | D | Common Stock | 65,000 | 38.70 | 2.52M | 109,398 | D | ↗ |
| 2025-12-26 | Green John L. | Officer | S-Sale | D | Common Stock | 77,000 | 38.68 | 2.98M | 131,834 | D | ↗ |
| 2025-12-17 | Sachs Jessica | Officer | A-Award | A | Stock Option (Right to Buy) | 65,000 | 39.45 | 2.56M | 65,000 | D | ↗ |
| 2025-12-17 | Robinson John Edward | Officer | A-Award | A | Common Stock | 320,000 | 0.00 | — | 370,000 | D | ↗ |
| 2025-12-17 | Robbins Andrew R | Director / Officer | A-Award | A | Common Stock | 185,000 | 0.00 | — | 185,000 | D | ↗ |
| 2025-12-17 | Pinnow Cole | Officer | A-Award | A | Stock Option (Right to Buy) | 65,000 | 39.45 | 2.56M | 65,000 | D | ↗ |
| 2025-12-17 | Kearns Evan | Officer | A-Award | A | Stock Option (Right to Buy) | 55,000 | 39.45 | 2.17M | 55,000 | D | ↗ |
| 2025-12-17 | Green John L. | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 53,841 | D | ↗ |
| 2025-10-01 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 1,642 | 14.13 | 23.2K | 1,642 | D | ↗ |
| 2025-07-10 | Fairmount Funds Management LLC | Director | P-Purchase | A | Common Stock | 2,777,777 | 9.00 | 25.00M | 9,003,418 | I | ↗ |
| 2025-07-01 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 3,314 | 7.22 | 23.9K | 3,314 | D | ↗ |
| 2025-06-04 | Shegog Todd | Director | A-Award | A | Stock Option (Right to Buy) | 44,700 | 5.64 | 252.1K | 44,700 | D | ↗ |
| 2025-06-04 | Ros Matthew | Director | A-Award | A | Stock Option (Right to Buy) | 44,700 | 5.64 | 252.1K | 44,700 | D | ↗ |
| 2025-06-04 | Morris Arlene | Director | A-Award | A | Stock Option (Right to Buy) | 44,700 | 5.64 | 252.1K | 44,700 | D | ↗ |
| 2025-06-04 | Harwin Peter Evan | Director | A-Award | A | Stock Option (Right to Buy) | 44,700 | 5.64 | 252.1K | 44,700 | D | ↗ |
| 2025-06-04 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 44,700 | 5.64 | 252.1K | 44,700 | D | ↗ |
| 2025-06-04 | CAIN CHRISTOPHER W. | Director | A-Award | A | Stock Option (Right to Buy) | 44,700 | 5.64 | 252.1K | 44,700 | D | ↗ |
| 2025-04-01 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 3,788 | 5.79 | 21.9K | 3,788 | D | ↗ |
| 2025-01-23 | Sachs Jessica | Officer | A-Award | A | Stock Option (Right to Buy) | 270,000 | 8.89 | 2.40M | 270,000 | D | ↗ |
| 2025-01-23 | Robinson John Edward | Officer | A-Award | A | Stock Option (Right to Buy) | 270,000 | 8.89 | 2.40M | 270,000 | D | ↗ |
| 2025-01-23 | Robbins Andrew R | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 915,000 | 8.89 | 8.13M | 915,000 | D | ↗ |
| 2025-01-23 | Pinnow Cole | Officer | A-Award | A | Stock Option (Right to Buy) | 240,000 | 8.89 | 2.13M | 240,000 | D | ↗ |
| 2025-01-23 | Kearns Evan | Officer | A-Award | A | Stock Option (Right to Buy) | 230,000 | 8.89 | 2.04M | 230,000 | D | ↗ |
| 2025-01-23 | Green John L. | Officer | A-Award | A | Stock Option (Right to Buy) | 270,000 | 8.89 | 2.40M | 270,000 | D | ↗ |
| 2025-01-14 | Pinnow Cole | Officer | P-Purchase | A | Common Stock | 43,750 | 7.60 | 332.4K | 45,848 | D | ↗ |
| 2025-01-01 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 2,785 | 7.80 | 21.7K | 2,785 | D | ↗ |
| 2024-10-01 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 2,034 | 10.75 | 21.9K | 2,034 | D | ↗ |
| 2024-07-01 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 2,462 | 8.94 | 22.0K | 2,462 | — | ↗ |
| 2024-06-10 | Fairmount Funds Management LLC | Director | M-Exempt | D | Series B Convertible Preferred Stock | 1,500 | 0.00 | — | 0 | — | ↗ |
| 2024-06-05 | Shegog Todd | Director | A-Award | A | Stock Option (Right to Buy) | 44,700 | 8.92 | 398.7K | 44,700 | — | ↗ |
| 2024-06-05 | Ros Matthew | Director | A-Award | A | Stock Option (Right to Buy) | 44,700 | 8.92 | 398.7K | 44,700 | — | ↗ |
| 2024-06-05 | Morris Arlene | Director | A-Award | A | Stock Option (Right to Buy) | 44,700 | 8.92 | 398.7K | 44,700 | — | ↗ |
| 2024-06-05 | Harwin Peter Evan | Director | A-Award | A | Stock Option (Right to Buy) | 44,700 | 8.92 | 398.7K | 44,700 | — | ↗ |
| 2024-06-05 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 44,700 | 8.92 | 398.7K | 44,700 | — | ↗ |
| 2024-06-05 | CAIN CHRISTOPHER W. | Director | A-Award | A | Stock Option (Right to Buy) | 44,700 | 8.92 | 398.7K | 44,700 | — | ↗ |
| 2024-05-25 | Pinnow Cole | Officer | A-Award | A | Stock Option (Right to Buy) | 525,000 | 8.22 | 4.32M | 525,000 | — | ↗ |
| 2024-04-01 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 3,213 | 6.90 | 22.2K | 3,213 | — | ↗ |
| 2024-03-28 | Fairmount Funds Management LLC | Director | J-Other | A | Common Stock | 286,851 | 0.00 | — | 4,725,641 | — | ↗ |
| 2024-02-16 | Fairmount Funds Management LLC | 10% Owner | A-Award | A | Series B Convertible Preferred Stock | 1,500 | 0.00 | — | 1,500 | — | ↗ |
| 2024-01-23 | Sachs Jessica | Officer | A-Award | A | Stock Option (Right to Buy) | 300,000 | 4.63 | 1.39M | 300,000 | — | ↗ |
| 2024-01-23 | Robinson John Edward | Officer | A-Award | A | Stock Option (Right to Buy) | 300,000 | 4.63 | 1.39M | 300,000 | — | ↗ |
| 2024-01-23 | Robbins Andrew R | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,100,000 | 4.63 | 5.09M | 1,100,000 | — | ↗ |
| 2024-01-23 | Kearns Evan | Officer | A-Award | A | Stock Option (Right to Buy) | 255,000 | 4.63 | 1.18M | 255,000 | — | ↗ |
| 2024-01-23 | Green John L. | Officer | A-Award | A | Stock Option (Right to Buy) | 300,000 | 4.63 | 1.39M | 300,000 | — | ↗ |
| 2024-01-02 | Ros Matthew | Director | A-Award | A | Stock Option (Right to Buy) | 3,051 | 6.24 | 19.0K | 3,051 | — | ↗ |
| 2024-01-02 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 3,298 | 6.24 | 20.6K | 3,298 | — | ↗ |
| 2023-10-02 | Ros Matthew | Director | A-Award | A | Stock Option (Right to Buy) | 2,170 | 9.55 | 20.7K | 2,170 | — | ↗ |
| 2023-10-02 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 2,345 | 9.55 | 22.4K | 2,345 | — | ↗ |
| 2023-07-03 | Ros Matthew | Director | A-Award | A | Stock Option (Right to Buy) | 1,743 | 11.96 | 20.8K | 1,743 | — | ↗ |
| 2023-07-03 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 1,884 | 11.96 | 22.5K | 1,884 | — | ↗ |
| 2023-06-09 | Fairmount Funds Management LLC | 10% Owner | P-Purchase | A | Common Stock | 800,000 | 12.00 | 9.60M | 3,272,124 | — | ↗ |
| 2023-06-07 | Shegog Todd | Director | A-Award | A | Stock Option (Right to Buy) | 36,700 | 11.70 | 429.4K | 36,700 | — | ↗ |
| 2023-06-07 | Ros Matthew | Director | A-Award | A | Stock Option (Right to Buy) | 36,700 | 11.70 | 429.4K | 36,700 | — | ↗ |
| 2023-06-07 | Morris Arlene | Director | A-Award | A | Stock Option (Right to Buy) | 36,700 | 11.70 | 429.4K | 36,700 | — | ↗ |
| 2023-06-07 | Harwin Peter Evan | Director | A-Award | A | Stock Option (Right to Buy) | 36,700 | 11.70 | 429.4K | 36,700 | — | ↗ |
| 2023-06-07 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 36,700 | 11.70 | 429.4K | 36,700 | — | ↗ |
| 2023-06-07 | CAIN CHRISTOPHER W. | Director | A-Award | A | Stock Option (Right to Buy) | 36,700 | 11.70 | 429.4K | 36,700 | — | ↗ |
| 2023-04-03 | Ros Matthew | Director | A-Award | A | Stock Option (Right to Buy) | 1,900 | 10.75 | 20.4K | 1,900 | — | ↗ |
| 2023-04-03 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 2,053 | 10.75 | 22.1K | 2,053 | — | ↗ |
| 2023-02-13 | Sachs Jessica | Officer | A-Award | A | Stock Option (Right to Buy) | 160,000 | 13.63 | 2.18M | 160,000 | — | ↗ |
| 2023-02-13 | Robinson John Edward | Officer | A-Award | A | Stock Option (Right to Buy) | 160,000 | 13.63 | 2.18M | 160,000 | — | ↗ |
| 2023-02-13 | Robbins Andrew R | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 525,000 | 13.63 | 7.16M | 525,000 | — | ↗ |
| 2023-02-13 | Kearns Evan | Officer | A-Award | A | Stock Option (Right to Buy) | 140,000 | 13.63 | 1.91M | 140,000 | — | ↗ |
| 2023-02-13 | Green John L. | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 13.63 | 2.04M | 150,000 | — | ↗ |
| 2023-01-03 | Ros Matthew | Director | A-Award | A | Stock Option (Right to Buy) | 1,792 | 7.19 | 12.9K | 1,792 | — | ↗ |
| 2023-01-03 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 1,862 | 7.19 | 13.4K | 1,862 | — | ↗ |
| 2022-10-03 | Ros Matthew | Director | A-Award | A | Stock Option (Right to Buy) | 1,419 | 9.08 | 12.9K | 1,419 | — | ↗ |
| 2022-10-03 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 1,474 | 9.08 | 13.4K | 1,474 | — | ↗ |
| 2022-07-01 | Ros Matthew | Director | A-Award | A | Stock Option (Right to Buy) | 2,194 | 9.39 | 20.6K | 2,194 | — | ↗ |
| 2022-07-01 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 2,279 | 9.39 | 21.4K | 2,279 | — | ↗ |
| 2022-06-30 | Sachs Jessica | Officer | A-Award | A | Common Stock | 622 | 7.40 | 4.6K | 622 | — | ↗ |
| 2022-06-16 | Fairmount Funds Management LLC | Director | P-Purchase | A | Common Stock | 1,200,000 | 8.25 | 9.90M | 2,472,124 | — | ↗ |
| 2022-06-07 | Shegog Todd | Director | A-Award | A | Stock Option (Right to Buy) | 30,700 | 0.00 | — | 30,700 | — | ↗ |
| 2022-06-07 | Ros Matthew | Director | A-Award | A | Stock Option (Right to Buy) | 30,700 | 0.00 | — | 30,700 | — | ↗ |
| 2022-06-07 | Morris Arlene | Director | A-Award | A | Stock Option (Right to Buy) | 30,700 | 0.00 | — | 30,700 | — | ↗ |
| 2022-06-07 | Harwin Peter Evan | Director | A-Award | A | Stock Option (Right to Buy) | 30,700 | 4.59 | 140.9K | 30,700 | — | ↗ |
| 2022-06-07 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 30,700 | 4.59 | 140.9K | 30,700 | — | ↗ |
| 2022-06-07 | CAIN CHRISTOPHER W. | Director | A-Award | A | Stock Option (Right to Buy) | 30,700 | 0.00 | — | 30,700 | — | ↗ |
| 2022-04-01 | Ros Matthew | Director | A-Award | A | Stock Option (Right to Buy) | 2,650 | 7.92 | 21.0K | 2,650 | — | ↗ |
| 2022-04-01 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 2,753 | 4.86 | 13.4K | 2,753 | — | ↗ |
| 2022-01-25 | Sachs Jessica | Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 7.60 | 1.90M | 250,000 | — | ↗ |
| 2022-01-25 | Robinson John Edward | Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 7.60 | 1.90M | 250,000 | — | ↗ |
| 2022-01-25 | Robbins Andrew R | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 690,000 | 7.60 | 5.24M | 690,000 | — | ↗ |
| 2022-01-25 | Kearns Evan | Officer | A-Award | A | Stock Option (Right to Buy) | 202,250 | 7.60 | 1.54M | 202,250 | — | ↗ |
| 2022-01-25 | Green John L. | Officer | A-Award | A | Stock Option (Right to Buy) | 225,000 | 7.60 | 1.71M | 225,000 | — | ↗ |
| 2022-01-03 | Ros Matthew | Director | A-Award | A | Stock Option (Right to Buy) | 2,256 | 8.70 | 19.6K | 2,256 | — | ↗ |
| 2022-01-03 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 2,329 | 8.70 | 20.3K | 2,329 | — | ↗ |
| 2021-12-31 | Sachs Jessica | Officer | A-Award | A | Common Stock | 674 | 6.82 | 4.6K | 674 | — | ↗ |
| 2021-10-01 | Ros Matthew | Director | A-Award | A | Stock Option (Right to Buy) | 2,463 | 8.54 | 21.0K | 2,463 | — | ↗ |
| 2021-10-01 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 2,385 | 8.54 | 20.4K | 2,385 | — | ↗ |
| 2021-07-01 | Ros Matthew | Director | A-Award | A | Stock Option (Right to Buy) | 2,225 | 8.02 | 17.8K | 2,225 | — | ↗ |
| 2021-07-01 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 2,513 | 8.02 | 20.2K | 2,513 | — | ↗ |
| 2021-05-03 | Kearns Evan | Officer | A-Award | A | Stock Option (Right to Buy) | 260,000 | 8.93 | 2.32M | 260,000 | — | ↗ |
| 2021-04-26 | Green John L. | Officer | S-Sale | D | Common Stock | 17,813 | 8.86 | 157.8K | 3,841 | — | ↗ |
| 2021-04-01 | Ros Matthew | Director | A-Award | A | Stock Option (Right to Buy) | 2,068 | 9.08 | 18.8K | 2,068 | — | ↗ |
| 2021-04-01 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 2,121 | 9.08 | 19.3K | 2,121 | — | ↗ |
| 2021-03-31 | Robinson John Edward | Officer | — | D | Stock Option (Right to Buy) | 500,000 | 8.78 | 4.39M | 0 | — | ↗ |
| 2021-03-11 | Shegog Todd | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 8.45 | 190.1K | 22,500 | — | ↗ |
| 2021-03-11 | Ros Matthew | Director | A-Award | A | Stock Option (Right to Buy) | 60,000 | 8.45 | 507.0K | 60,000 | — | ↗ |
| 2021-03-11 | Morris Arlene | Director | A-Award | A | Stock Option (Right to Buy) | 60,000 | 8.45 | 507.0K | 60,000 | — | ↗ |
| 2021-03-11 | Harwin Peter Evan | Director | A-Award | A | Stock Option (Right to Buy) | 60,000 | 8.45 | 507.0K | 60,000 | — | ↗ |
| 2021-03-11 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 60,000 | 8.45 | 507.0K | 60,000 | — | ↗ |
| 2021-03-11 | CAIN CHRISTOPHER W. | Director | A-Award | A | Stock Option (Right to Buy) | 60,000 | 8.45 | 507.0K | 60,000 | — | ↗ |
| 2021-02-25 | Green John L. | Officer | A-Award | A | Common Stock | 524 | 0.00 | — | 21,654 | — | ↗ |
| 2021-02-22 | Shegog Todd | Director | A-Award | A | Stock Option (Right to Buy) | 37,500 | 8.59 | 322.1K | 37,500 | — | ↗ |
| 2021-02-10 | Sachs Jessica | Officer | A-Award | A | Stock Option (Right to Buy) | 126,500 | 10.17 | 1.29M | 126,500 | — | ↗ |
| 2021-02-10 | Robbins Andrew R | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 315,200 | 10.17 | 3.21M | 315,200 | — | ↗ |
| 2021-02-10 | Green John L. | Officer | A-Award | A | Stock Option (Right to Buy) | 270,746 | 10.17 | 2.75M | 270,746 | — | ↗ |
| 2021-02-01 | Sachs Jessica | Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 9.10 | 3.64M | 400,000 | — | ↗ |
| 2021-01-04 | Ros Matthew | Director | A-Award | A | Stock Option (Right to Buy) | 1,641 | 7.62 | 12.5K | 1,641 | — | ↗ |
| 2021-01-04 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 1,575 | 7.62 | 12.0K | 1,575 | — | ↗ |
| 2020-12-07 | Robbins Andrew R | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 456,693 | 12.76 | 5.83M | 456,693 | — | ↗ |
| 2020-12-01 | Green John L. | Officer | A-Award | A | Common Stock | 1,748 | 0.00 | — | 1,748 | — | ↗ |
| 2020-10-23 | Robbins Andrew R | Officer | A-Award | A | Stock Option (Right to Buy) | 7,442,421 | 2.79 | 20.76M | 7,442,421 | — | ↗ |
| 2020-10-13 | Green John L. | Officer | A-Award | A | Stock Option (Right to Buy) | 695,700 | 2.89 | 2.01M | 695,700 | — | ↗ |
| 2020-10-01 | Ros Matthew | Director | A-Award | A | Stock Option (Right to Buy) | 9,247 | 2.26 | 20.9K | 9,247 | — | ↗ |
| 2020-10-01 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 8,878 | 2.26 | 20.1K | 8,878 | — | ↗ |
| 2020-08-27 | Harwin Peter Evan | Director | A-Award | A | Director Stock Option (Right to Buy) | 28,661 | 2.77 | 79.4K | 28,661 | — | ↗ |
| 2020-08-27 | CAIN CHRISTOPHER W. | Director | A-Award | A | Director Stock Option (Right to Buy) | 28,661 | 2.77 | 79.4K | 28,661 | — | ↗ |
| 2020-08-13 | Venrock Healthcare Capital Partners III, L.P. | 10% Owner | — | I | Series A Non-Voting Convertible Preferred Stock | 13,636,000 | 0.00 | — | 0 | — | ↗ |
| 2020-07-06 | Harwin Peter Evan | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-07-06 | Green John L. | Officer | F-InKind | D | Common Stock | 31,873 | 2.20 | 70.1K | 77,586 | — | ↗ |
| 2020-07-06 | Fairmount Funds Management LLC | 10% Owner | J-Other | A | Series A Convertible Preferred Stock | 36,465 | 0.00 | — | 36,465 | — | ↗ |
| 2020-07-06 | CAIN CHRISTOPHER W. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-07-01 | Ros Matthew | Director | A-Award | A | Stock Option (Right to Buy) | 35,280 | 0.47 | 16.6K | 35,280 | — | ↗ |
| 2020-07-01 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 38,487 | 0.47 | 18.1K | 38,487 | — | ↗ |
| 2020-07-01 | Booth Bruce | Director | A-Award | A | Stock Option (Right to Buy) | 61,338 | 0.47 | 28.8K | 61,338 | — | ↗ |
| 2020-07-01 | Aldag Jorn | Director | A-Award | A | Stock Option (Right to Buy) | 40,090 | 0.47 | 18.8K | 40,090 | — | ↗ |
| 2020-06-09 | Ros Matthew | Director | A-Award | A | Stock Option (Right to Buy) | 14,331 | 0.63 | 9.0K | 14,331 | — | ↗ |
| 2020-06-09 | Morris Arlene | Director | A-Award | A | Stock Option (Right to Buy) | 14,331 | 0.63 | 9.0K | 14,331 | — | ↗ |
| 2020-06-09 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 14,331 | 0.63 | 9.0K | 14,331 | — | ↗ |
| 2020-06-09 | Booth Bruce | Director | A-Award | A | Stock Option (Right to Buy) | 14,331 | 0.63 | 9.0K | 14,331 | — | ↗ |
| 2020-06-09 | Aldag Jorn | Director | A-Award | A | Stock Option (Right to Buy) | 14,331 | 0.63 | 9.0K | 14,331 | — | ↗ |
| 2020-05-12 | CAMPANA DARIO | 10% Owner | S-Sale | D | Common Stock | 98,200 | 0.46 | 45.5K | 3,095,114 | — | ↗ |
| 2020-05-11 | CAMPANA DARIO | 10% Owner | S-Sale | D | Common Stock | 22,281 | 0.46 | 10.3K | 3,271,033 | — | ↗ |
| 2020-05-08 | CAMPANA DARIO | 10% Owner | S-Sale | D | Common Stock | 100,000 | 0.46 | 46.4K | 3,293,314 | — | ↗ |
| 2020-05-07 | CAMPANA DARIO | 10% Owner | S-Sale | D | Common Stock | 100,000 | 0.41 | 41.4K | 3,393,314 | — | ↗ |
| 2020-05-06 | CAMPANA DARIO | 10% Owner | S-Sale | D | Common Stock | 1,800 | 0.40 | 721.62 | 3,493,314 | — | ↗ |
| 2020-05-05 | CAMPANA DARIO | 10% Owner | S-Sale | D | Common Stock | 135,484 | 0.40 | 54.4K | 3,495,114 | — | ↗ |
| 2020-05-04 | CAMPANA DARIO | 10% Owner | S-Sale | D | Common Stock | 4,795 | 0.40 | 1.9K | 3,630,598 | — | ↗ |
| 2020-05-01 | CAMPANA DARIO | 10% Owner | S-Sale | D | Common Stock | 800 | 0.41 | 328.00 | 3,635,393 | — | ↗ |
| 2020-04-30 | CAMPANA DARIO | 10% Owner | S-Sale | D | Common Stock | 75,994 | 0.40 | 30.6K | 3,636,193 | — | ↗ |
| 2020-04-29 | CAMPANA DARIO | 10% Owner | S-Sale | D | Common Stock | 382,927 | 0.41 | 155.5K | 3,712,187 | — | ↗ |
| 2020-04-28 | CAMPANA DARIO | 10% Owner | S-Sale | D | Common Stock | 15,048 | 0.41 | 6.2K | 4,095,114 | — | ↗ |
| 2020-04-27 | CAMPANA DARIO | 10% Owner | S-Sale | D | Common Stock | 242,579 | 0.40 | 97.8K | 4,110,162 | — | ↗ |
| 2020-04-20 | CAMPANA DARIO | 10% Owner | S-Sale | D | Common Stock | 12,606 | 0.40 | 5.0K | 4,352,741 | — | ↗ |
| 2020-04-17 | CAMPANA DARIO | 10% Owner | S-Sale | D | Common Stock | 65,540 | 0.39 | 25.6K | 4,365,347 | — | ↗ |
| 2020-04-16 | CAMPANA DARIO | 10% Owner | S-Sale | D | Common Stock | 600 | 0.38 | 229.56 | 4,430,887 | — | ↗ |
| 2020-04-15 | CAMPANA DARIO | 10% Owner | S-Sale | D | Common Stock | 82,782 | 0.38 | 31.8K | 4,431,487 | — | ↗ |
| 2020-04-14 | CAMPANA DARIO | 10% Owner | S-Sale | D | Common Stock | 44,006 | 0.40 | 17.6K | 4,514,269 | — | ↗ |
| 2020-04-09 | CAMPANA DARIO | 10% Owner | S-Sale | D | Common Stock | 420,292 | 0.33 | 138.1K | 4,613,242 | — | ↗ |
| 2020-04-08 | CAMPANA DARIO | 10% Owner | S-Sale | D | Common Stock | 100 | 0.35 | 35.10 | 5,033,534 | — | ↗ |
| 2020-04-07 | CAMPANA DARIO | 10% Owner | S-Sale | D | Common Stock | 11,400 | 0.35 | 4.0K | 5,033,634 | — | ↗ |
| 2020-04-06 | Ros Matthew | Director | A-Award | A | Stock Option (Right to Buy) | 49,887 | 0.35 | 17.4K | 49,887 | — | ↗ |
| 2020-04-06 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 54,422 | 0.35 | 19.0K | 54,422 | — | ↗ |
| 2020-04-06 | CAMPANA DARIO | 10% Owner | S-Sale | D | Common Stock | 50,080 | 0.35 | 17.5K | 5,045,034 | — | ↗ |
| 2020-04-06 | Booth Bruce | Director | A-Award | A | Stock Option (Right to Buy) | 86,735 | 0.35 | 30.3K | 86,735 | — | ↗ |
| 2020-04-06 | Aldag Jorn | Director | A-Award | A | Stock Option (Right to Buy) | 56,690 | 0.35 | 19.8K | 56,690 | — | ↗ |
| 2020-02-11 | Sachs Jessica | Officer | A-Award | A | Stock Option | 133,200 | 0.80 | 106.6K | 133,200 | — | ↗ |
| 2020-02-11 | Osborne Matthew Scott | Officer | A-Award | A | Stock Option | 160,400 | 0.80 | 128.3K | 160,400 | — | ↗ |
| 2020-02-11 | HODGE GEOFFREY | Officer | A-Award | A | Stock Option | 112,400 | 0.80 | 89.9K | 112,400 | — | ↗ |
| 2020-02-11 | Green John L. | Officer | A-Award | A | Stock Option | 64,400 | 0.80 | 51.5K | 64,400 | — | ↗ |
| 2020-02-11 | Ettenberg Seth | Officer | A-Award | A | Stock Option | 153,600 | 0.80 | 122.9K | 153,600 | — | ↗ |
| 2020-01-02 | Ros Matthew | Director | A-Award | A | Stock Option (Right to Buy) | 24,274 | 0.72 | 17.5K | 24,274 | — | ↗ |
| 2020-01-02 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 26,480 | 0.72 | 19.1K | 26,480 | — | ↗ |
| 2020-01-02 | Booth Bruce | Director | A-Award | A | Stock Option (Right to Buy) | 39,996 | 0.72 | 28.8K | 39,996 | — | ↗ |
| 2020-01-02 | Aldag Jorn | Director | A-Award | A | Stock Option (Right to Buy) | 29,790 | 0.72 | 21.4K | 29,790 | — | ↗ |
| 2019-11-19 | Green John L. | Officer | A-Award | A | Restricted Stock Units | 109,459 | 0.00 | — | 109,459 | — | ↗ |
| 2019-11-19 | Ettenberg Seth | Officer | A-Award | A | Stock Option (Right to Buy) | 280,000 | 0.69 | 193.2K | 280,000 | — | ↗ |
| 2019-10-01 | Ros Matthew | Director | A-Award | A | Stock Option (Right to Buy) | 12,509 | 1.41 | 17.6K | 12,509 | — | ↗ |
| 2019-10-01 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 13,646 | 1.41 | 19.2K | 13,646 | — | ↗ |
| 2019-10-01 | Booth Bruce | Director | A-Award | A | Stock Option (Right to Buy) | 20,611 | 1.41 | 29.1K | 20,611 | — | ↗ |
| 2019-10-01 | Aldag Jorn | Director | A-Award | A | Stock Option (Right to Buy) | 15,352 | 1.41 | 21.6K | 15,352 | — | ↗ |
| 2019-07-26 | Ros Matthew | Director | A-Award | A | Stock Option (Right to Buy) | 28,661 | 2.05 | 58.8K | 28,661 | — | ↗ |
| 2019-07-26 | Morris Arlene | Director | A-Award | A | Stock Option (Right to Buy) | 28,661 | 2.05 | 58.8K | 28,661 | — | ↗ |
| 2019-07-19 | Sachs Jessica | Officer | A-Award | A | Stock Option (Right to Buy) | 123,800 | 2.61 | 323.1K | 123,800 | — | ↗ |
| 2019-07-15 | Sachs Jessica | Officer | — | D | Stock Option (Right to Buy) | 22,419 | 3.52 | 78.9K | 0 | — | ↗ |
| 2019-07-01 | Booth Bruce | Director | A-Award | A | Stock Option (Right to Buy) | 10,285 | 2.41 | 24.8K | 10,285 | — | ↗ |
| 2019-07-01 | Aldag Jorn | Director | A-Award | A | Stock Option (Right to Buy) | 7,608 | 2.41 | 18.3K | 7,608 | — | ↗ |
| 2019-06-24 | Osborne Matthew Scott | Officer | A-Award | A | Stock Option (Right to Buy) | 190,000 | 2.44 | 463.6K | 190,000 | — | ↗ |
| 2019-06-18 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 14,331 | 2.70 | 38.7K | 14,331 | — | ↗ |
| 2019-06-18 | Booth Bruce | Director | A-Award | A | Stock Option (Right to Buy) | 14,331 | 2.70 | 38.7K | 14,331 | — | ↗ |
| 2019-06-14 | Ratcliffe Liam | Director | A-Award | A | Stock Option (Right to Buy) | 7,881 | 2.43 | 19.2K | 7,881 | — | ↗ |
| 2019-06-14 | PEREZ ROBERT J | Director | A-Award | A | Stock Option (Right to Buy) | 7,131 | 2.43 | 17.3K | 7,131 | — | ↗ |
| 2019-04-24 | Green John L. | Officer | A-Award | A | Stock Option (Right to Buy) | 16,814 | 3.52 | 59.2K | 16,814 | — | ↗ |
| 2019-04-19 | Green John L. | Officer | A-Award | A | Stock Option (Right to Buy) | 21,017 | 3.60 | 75.7K | 21,017 | — | ↗ |
| 2019-04-01 | Ratcliffe Liam | Director | A-Award | A | Stock Option (Right to Buy) | 4,829 | 4.40 | 21.2K | 4,829 | — | ↗ |
| 2019-04-01 | PEREZ ROBERT J | Director | A-Award | A | Stock Option (Right to Buy) | 4,369 | 4.40 | 19.2K | 4,369 | — | ↗ |
| 2019-04-01 | Ferrante Karen Jean | Director | A-Award | A | Stock Option (Right to Buy) | 4,047 | 4.40 | 17.8K | 4,047 | — | ↗ |
| 2019-04-01 | Booth Bruce | Director | A-Award | A | Stock Option (Right to Buy) | 6,714 | 4.40 | 29.5K | 6,714 | — | ↗ |
| 2019-04-01 | Aldag Jorn | Director | A-Award | A | Stock Option (Right to Buy) | 4,966 | 4.40 | 21.9K | 4,966 | — | ↗ |
| 2019-03-25 | Ettenberg Seth | Officer | M-Exempt | D | Stock Option (Right to Buy) | 11,485 | 0.18 | 2.1K | 329,145 | — | ↗ |
| 2019-03-01 | WILSON CHARLES | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 174,400 | 4.36 | 760.4K | 174,400 | — | ↗ |
| 2019-03-01 | VASCONCELLES MICHAEL | Officer | A-Award | A | Stock Option (Right to Buy) | 61,900 | 4.36 | 269.9K | 61,900 | — | ↗ |
Executive team
Top executives
Shares Outstanding
162.31M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Andrew Robbins Chief Executive Officer | 724.6K | 21.6K | 12.99M | 13.45M | 561.6K | 14.0K | 27.76M | 95.24% | ↗ |
| 2 | 2025 | Jessica Sachs Chief Medical Officer | 549.4K | 12.3K | 4.54M | 3.75M | 320.9K | 14.0K | 9.18M | 90.23% | ↗ |
| 3 | 2025 | John Robinson Chief Scientific Officer | 532.0K | 12.0K | 4.54M | 3.75M | 310.8K | 14.0K | 9.15M | 90.51% | ↗ |
| 4 | 2025 | Cole Pinnow Chief Commercial Officer | 482.3K | 9.6K | 4.54M | 3.55M | 248.8K | 14.0K | 8.84M | 91.46% | ↗ |
| 5 | 2025 | John Green Chief Financial Officer | 510.7K | 11.5K | 3.97M | 3.75M | 298.1K | 14.0K | 8.55M | 90.24% | ↗ |
| 6 | 2024 | Andrew Robbins Chief Executive Officer | 692.0K | — | — | 3.73M | 477.5K | 13.8K | 4.92M | 75.94% | ↗ |
| 7 | 2024 | Cole Pinnow Chief Commercial Officer | 265.4K | 50.0K | 263.0K | 3.26M | 127.8K | — | 3.97M | 88.84% | ↗ |
| 8 | 2024 | Jessica Sachs Chief Medical Officer | 527.4K | — | — | 1.02M | 272.9K | 13.8K | 1.83M | 55.57% | ↗ |
| 9 | 2024 | John Robinson Chief Scientific Officer | 510.8K | — | — | 1.02M | 264.3K | 13.8K | 1.81M | 56.35% | ↗ |
| 10 | 2024 | John Green Chief Financial Officer | 490.0K | — | — | 1.02M | 225.4K | 13.8K | 1.75M | 58.28% | ↗ |
| 11 | 2023 | Andrew Robbins Chief Executive Officer | 656.1K | 393.7K | 1.87M | 4.96M | — | 13.2K | 7.90M | 86.54% | ↗ |
| 12 | 2023 | Jessica Sachs Chief Medical Officer | 507.2K | 253.6K | 713.6K | 1.51M | — | 13.2K | 3.00M | 74.20% | ↗ |
| 13 | 2023 | Jessica Sachs, M.D. Chief Medical Officer | 507.2K | 253.6K | 713.6K | 1.51M | — | 13.2K | 3.00M | 74.20% | ↗ |
| 14 | 2023 | John Robinson, Ph.D. Chief Scientific Officer | 491.1K | 245.6K | 713.6K | 1.51M | — | 13.2K | 2.98M | 74.80% | ↗ |
| 15 | 2023 | John Robinson Chief Scientific Officer | 491.1K | 245.6K | 713.6K | 1.51M | — | 13.2K | 2.98M | 74.80% | ↗ |
| 16 | 2022 | Andrew Robbins Chief Executive Officer | 624.3K | 344.9K | — | 3.41M | — | 12.2K | 4.39M | 77.65% | ↗ |
| 17 | 2022 | Jessica Sachs, M.D. Chief Medical Officer | 482.6K | 177.7K | — | 1.24M | — | 12.2K | 1.91M | 64.75% | ↗ |
| 18 | 2022 | John Robinson, Ph.D. Chief Scientific Officer | 454.2K | 167.3K | — | 1.24M | — | 12.2K | 1.87M | 66.10% | ↗ |
| 19 | 2021 | Jessica Sachs, M.D. Chief Medical Officer | 415.8K | 167.9K | — | 3.21M | — | 11.6K | 3.81M | 84.37% | ↗ |
| 20 | 2021 | John Robinson, Ph.D. Chief Scientific Officer | 315.5K | 128.1K | — | 3.02M | — | 11.6K | 3.47M | 86.89% | ↗ |
| 21 | 2021 | Andrew Robbins Chief Executive Officer | 592.6K | 357.1K | — | 1.90M | — | 11.6K | 2.86M | 66.42% | ↗ |
| 22 | 2020 | Andrew Robbins Chief Executive Officer | 101.7K | 65.2K | — | 17.69M | — | — | 17.86M | 99.07% | ↗ |
| 23 | 2020 | John Green Chief Financial Officer | 324.0K | 440.0K | — | 1.38M | — | — | 2.14M | 64.29% | ↗ |
| 24 | 2020 | Charles Wilson, Ph.D. Former Chief Executive Officer | 481.3K | — | — | — | — | 1.32M | 1.80M | 0.00% | ↗ |
| 25 | 2020 | Jessica Sachs, M.D. Chief Medical Officer | 278.7K | — | — | 115.4K | — | 795.3K | 1.19M | 9.70% | ↗ |
| 26 | 2019 | Charles Wilson, Ph.D. Former Chief Executive Officer | 543.4K | 232.3K | — | 941.7K | — | — | 1.72M | 54.83% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Andrew R. Robbins | President, Chief Executive Officer & Director | 1M | male |
| Jessica Sachs | Chief Medical Officer | 896.6K | — |
| John Edward Robinson | Chief Scientific Officer | 868.7K | — |
| Cole Pinnow | Chief Commercial Officer | 754.6K | male |
| John L. Green | Chief Financial Officer & Principal Accounting Officer | 729.2K | male |
| Erin Schellhammer | Chief People Officer | — | female |
| Evan D. Kearns | Chief Legal Officer & Corporate Secretary | — | male |
| Abb Hayden | Senior Vice President of Sales | — | male |
| Rachael Easton | Senior Vice President of Clinical Development | — | — |
| Brad Barnett | Chief Technology Officer | — | male |
| Brad Fell | Senior Vice President of Chemistry | — | — |
| Christi Waarich | Senior Director of Investor Relations | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2022-12-12 | 2023-01-20 | Christopher L. Jacobs | NY27 | — | Purchase | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for COGT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
